BMO Capital Markets Forecasts Strong Price Appreciation for LB Pharmaceuticals (NASDAQ:LBRX) Stock

Posted by Geri Gentry on Aug 12th, 2026

LB Pharmaceuticals (NASDAQ:LBRX – Get Free Report) had its price target hoisted by investment analysts at BMO Capital Markets from $46.00 to $54.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ price target indicates a potential upside of 19.13% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Piper Sandler reissued an “overweight” rating and issued a $78.00 price target on shares of LB Pharmaceuticals in a report on Monday, August 3rd. Weiss Ratings raised shares of LB Pharmaceuticals from a “sell (d-)” rating to a “sell (d+)” rating in a report on Friday, July 24th. Wolfe Research initiated coverage on shares of LB Pharmaceuticals in a research report on Tuesday, July 7th. They set an “outperform” rating and a $45.00 price target for the company. Wall Street Zen raised shares of LB Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. Finally, Roth Capital reiterated a “buy” rating and issued a $37.00 price objective on shares of LB Pharmaceuticals in a research report on Sunday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.12.

Check Out Our Latest Research Report on LB Pharmaceuticals

LB Pharmaceuticals Price Performance

Shares of NASDAQ LBRX opened at $45.33 on Wednesday. LB Pharmaceuticals has a 1 year low of $13.36 and a 1 year high of $49.14. The stock has a market capitalization of $1.30 billion and a P/E ratio of -26.20. The company has a 50-day moving average price of $33.98 and a 200-day moving average price of $28.95.

LB Pharmaceuticals (NASDAQ:LBRX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.87). As a group, equities research analysts anticipate that LB Pharmaceuticals will post -3.55 earnings per share for the current fiscal year.

Institutional Trading of LB Pharmaceuticals

A number of hedge funds have recently made changes to their positions in LBRX. Deep Track Capital LP bought a new position in LB Pharmaceuticals in the third quarter valued at $52,941,000. RA Capital Management L.P. raised its holdings in shares of LB Pharmaceuticals by 24.3% during the 4th quarter. RA Capital Management L.P. now owns 2,208,604 shares of the company’s stock valued at $49,164,000 after buying an additional 431,646 shares in the last quarter. TCG Crossover Management LLC bought a new stake in LB Pharmaceuticals in the 3rd quarter worth approximately $27,554,000. JPMorgan Chase & Co. grew its position in LB Pharmaceuticals by 56.1% during the fourth quarter. JPMorgan Chase & Co. now owns 1,611,482 shares of the company’s stock valued at $35,872,000 after acquiring an additional 578,879 shares during the last quarter. Finally, Spruce Street Capital LP lifted its holdings in shares of LB Pharmaceuticals by 36.9% in the 1st quarter. Spruce Street Capital LP now owns 1,376,159 shares of the company’s stock worth $33,645,000 after acquiring an additional 370,566 shares during the last quarter.

LB Pharmaceuticals Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.